A Tumor Blueprint for Each Patient: UK’s First Patient Receives Personalized DNA Lung Cancer Vaccine

For cancer vaccines, the real challenge is often not prompting the immune system to attack, but identifying a target found only on the tumor without harming normal tissue. The UK’s NEOVACC trial has now taken its first clinical step: the first patient with advanced non-small cell lung cancer has received a therapeutic DNA vaccine made according to the genetic characteristics of their tumor. This is not a vaccine to prevent lung cancer, but an attempt to retrain immune cells after cancer has developed to recognize the patient’s own tumor.

Each participant must first undergo a genetic comparison of tumor and normal cells to identify mutations unique to the cancer cells. The research team then uses algorithms, genomic analysis, and bioinformatics methods to select neoantigens more likely to be recognized by the immune system and designs a personalized vaccine based on them. myNEO Therapeutics provides the neoantigen selection technology, but whether the targets predicted by computers can actually induce an effective immune response in humans must still be verified through subsequent sample analysis.

Information on the selected neoantigens is encoded into a vaccine component called “doggybone DNA” (dbDNA). This is an enzymatically manufactured, linear double-stranded DNA vector with covalently closed ends. Because production does not rely on bacterial culture, the developers hope to shorten the time from personalized design to vaccine delivery. This cell-free manufacturing process is central to whether highly customized treatment can work in practice, but NEOVACC is also the first personalized dbDNA cancer vaccine to enter human testing, and clinical experience with its side effects in humans and manufacturing consistency remains limited.

NEOVACC is sponsored by the University of Liverpool and conducted at The Clatterbridge Cancer Centre. It is expected to enroll ten patients with non-small cell lung cancer who have not derived sufficient benefit from standard immunotherapy. The vaccine is injected into muscle using a needle-free PharmaJet injector and administered in combination with the immune checkpoint inhibitor pembrolizumab. According to the trial registration, it is administered once every three weeks for the first 24 weeks and once every six weeks thereafter. The study received a favorable research ethics review opinion in April 2025 and is registered under ISRCTN11752949.

The primary purpose of this phase 1 study is not to prove that the vaccine can extend survival, but to assess safety, tolerability, and immune responses. Through physical examinations, blood tests, tumor biopsies, long-term blood sampling, and leukapheresis, researchers will track whether the vaccine teaches immune cells to recognize and attack cancer cells. Most follow-up arrangements will be coordinated with the patients’ existing standard-care appointments.

A ten-person study cannot determine whether the treatment is more effective than current therapies, and there is no control group to rule out effects caused by pembrolizumab itself. Every link in the chain—from algorithm-selected neoantigens and rapid manufacturing of individual batches to whether immune responses translate into tumor shrinkage or longer survival—still requires validation. The first patient’s vaccination therefore represents the first clinical implementation of this technological chain in the UK, not proof that the treatment is effective against lung cancer.

Only if the study demonstrates acceptable safety and detects immune responses against the intended neoantigens in blood or tumor tissue could it provide a basis for subsequent larger trials. NEOVACC is testing not only a vaccine, but also whether a personalized medicine workflow can repeatedly complete sequencing, computation, manufacturing, and administration within clinical time constraints.